Determination of the Parameters of Acute Toxicity of the Epophen Antihypoxant Drug on Laboratory Animals
https://doi.org/10.33647/2074-5982-18-1-63-66
Abstract
The energy deficit underlying any form of hypoxia leads to qualitatively similar metabolic and structural changes in various organs and tissues. Antihypoxants are capable of preventing, reducing or eliminating the manifestations of hypoxia by maintaining energy metabolism in a mode sufficient for preserving the structure and functional activity of cells at least at an acceptable minimum level. This study aims to determine the acute toxicity of a new antihypoxant drug, Epophen. The study was conducted on female BALB/C mice with a body weight of 19±2 g. It was found that the studied drug belongs to the 4th class of moderately toxic substances in accordance with GOST 12.1.007-76.
About the Authors
K. S. Ostrenko
The All-Russian Research Institute of Animal Physiology, Biochemistry and Nutrition — the Branch of the Federal Research Center for Animal Husbandry named after Academy Member L.K. Ernst
Russian Federation
Russian Federation
Konstantin S. Ostrenko, Dr. Sci. (Biol.)
249013, Kaluga Region, Borovsk, Institute Village
A. N. Оvcharova
The All-Russian Research Institute of Animal Physiology, Biochemistry and Nutrition — the Branch of the Federal Research Center for Animal Husbandry named after Academy Member L.K. Ernst
Russian Federation
Russian Federation
Anastasia N. Ovcharova, Cand. Sci. (Biol.)
249013, Kaluga Region, Borovsk, Institute Village
O. P. Egorova
Scientific and Production Company “Iglessia”
Russian Federation
Russian Federation
Olga P. Yegorova
115516, Moscow, Bakinskaya Str., 18
References
1. Belen’kij M.L. Elementy kolichestvennoj ocenki farmakologicheskogo effekta [Elements of quantitative assessment of pharmacological effect]. Leningrad: Gosmedizdat Publ., 1963:152. (In Russian).
2. Karpova O.A., Mikhina L.V., Denisov A.A., Kuz’mich M.K. Izuchenie antimutagennoj aktivnosti gipoksena in vivo [Study of the antimutagenic activity of hypoxen in vivo]. Éksperimentalnaya i klinicheskaya farmakologiya [Experimental and Clinical Pharmacology]. 2002;65(3):54–56. (In Russian).
3. Devun F., Walter L., Belliere J., Cottet-Rousselle C., Leverve X., Fontaine E. Ubiquinone analogs: a mitochondrial permeability transition pore-dependent pathway to selective cell death. PLoS One. 2010;5:e11792. DOI: 10.1371/journal.pone.0011792.
4. Garrido-Maraver J., Cordero M.D., Oropesa-Avila M., Vega A.F., de la Mata M., Pavon A.D., Alcocer-Gomez E., Calero C.P., Paz M.V., Alanis M., de Lavera I., Cotan D., Sanchez-Alcazar J.A. Clinical applications of coenzyme Q10. Front Biosci (Landmark Ed). 2014;19:619–633. DOI: 10.2741/4231.
5. Nohl H., Gille L., Staniek K. The biochemical, pathophysiological, and medical aspects of ubiquinone function. Ann. N.-Y. Acad. Sci. 1998;20:394–409. DOI: 10.1111/j.1749-6632.1998.tb09919.x.
6. Vadhanavikit S., Ganther H.E. Decreased ubiquinone levels in tissues of rats deficient in selenium. Biochem. Biophys. Res. Commun. 1993;190(3):921–926. DOI: 10.1006/bbrc.1993.1137
Review
For citations:
Ostrenko K.S., Оvcharova A.N., Egorova O.P. Determination of the Parameters of Acute Toxicity of the Epophen Antihypoxant Drug on Laboratory Animals. Journal Biomed. 2022;18(1):63-66. (In Russ.) https://doi.org/10.33647/2074-5982-18-1-63-66
Views:
392
Email this article 
